Abbott reported adjusted earnings of 63 cents per share on revenue of $7.5 billion, a 2% year-over-year increase.
Analysts polled by FactSet were expecting the company to report earnings of 61 cents per share on revenue of $7.48 billion.
"We're right on track with our expectations to start the year," said Abbott's Chairman and CEO Miles D. White. "All of our key long-term growth drivers are performing well and we're targeting another year of strong sales and earnings growth."
The company reported a 5.5% increase in worldwide medical device sales, led by double-digit growth in its electrophysiology, heart failure, structural heart and diabetes care devices.
For the year, the company expects to earn between $3.15 and $3.25 per share, which is in line with Wall Street's $3.21 guidance. For the second quarter, the company expects to earn between 79 cents and 81 cents per share, also in line with analysts' expectations of 80 cents.
Abbott Laboratories is a key holding in Jim Cramer's Action Alerts PLUS charitable trust.